Cargando…

Immunomodulatory Role of NK Cells during Antiviral Antibody Therapy

Monoclonal antibodies (mAbs) are now considered as a therapeutic approach to prevent and treat severe viral infections. Using a mouse retroviral model, we showed that mAbs induce protective immunity (vaccinal effects). Here, we investigated the role of natural killer (NK) cells on this effect. NK ce...

Descripción completa

Detalles Bibliográficos
Autores principales: Naranjo-Gomez, Mar, Cahen, Marine, Lambour, Jennifer, Boyer-Clavel, Myriam, Pelegrin, Mireia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7914599/
https://www.ncbi.nlm.nih.gov/pubmed/33567792
http://dx.doi.org/10.3390/vaccines9020137
_version_ 1783657041111285760
author Naranjo-Gomez, Mar
Cahen, Marine
Lambour, Jennifer
Boyer-Clavel, Myriam
Pelegrin, Mireia
author_facet Naranjo-Gomez, Mar
Cahen, Marine
Lambour, Jennifer
Boyer-Clavel, Myriam
Pelegrin, Mireia
author_sort Naranjo-Gomez, Mar
collection PubMed
description Monoclonal antibodies (mAbs) are now considered as a therapeutic approach to prevent and treat severe viral infections. Using a mouse retroviral model, we showed that mAbs induce protective immunity (vaccinal effects). Here, we investigated the role of natural killer (NK) cells on this effect. NK cells are effector cells that are crucial to control viral propagation upon mAb treatment. However, their immunomodulatory activity during antiviral mAb immunotherapies has been little studied. Our data reveal that the mAb treatment of infected mice preserves the functional activation of NK cells. Importantly, functional NK cells play an essential role in preventing immune dysfunction and inducing antiviral protective immunity upon mAb therapy. Thus, NK cell depletion in mAb-treated, viral-infected mice leads to the upregulation of molecules involved in immunosuppressive pathways (i.e., PD-1, PD-L1 and CD39) on dendritic cells and T cells. NK cell depletion also abrogates the vaccinal effects induced by mAb therapy. Our data also reveal a role for IFNγ-producing NK cells in the enhancement of the B-cell responses through the potentiation of the B-cell helper properties of neutrophils. These findings suggest that preserved NK cell functions and counts might be required for achieving mAb-induced protective immunity. They open new prospects for improving antiviral immunotherapies.
format Online
Article
Text
id pubmed-7914599
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-79145992021-03-01 Immunomodulatory Role of NK Cells during Antiviral Antibody Therapy Naranjo-Gomez, Mar Cahen, Marine Lambour, Jennifer Boyer-Clavel, Myriam Pelegrin, Mireia Vaccines (Basel) Article Monoclonal antibodies (mAbs) are now considered as a therapeutic approach to prevent and treat severe viral infections. Using a mouse retroviral model, we showed that mAbs induce protective immunity (vaccinal effects). Here, we investigated the role of natural killer (NK) cells on this effect. NK cells are effector cells that are crucial to control viral propagation upon mAb treatment. However, their immunomodulatory activity during antiviral mAb immunotherapies has been little studied. Our data reveal that the mAb treatment of infected mice preserves the functional activation of NK cells. Importantly, functional NK cells play an essential role in preventing immune dysfunction and inducing antiviral protective immunity upon mAb therapy. Thus, NK cell depletion in mAb-treated, viral-infected mice leads to the upregulation of molecules involved in immunosuppressive pathways (i.e., PD-1, PD-L1 and CD39) on dendritic cells and T cells. NK cell depletion also abrogates the vaccinal effects induced by mAb therapy. Our data also reveal a role for IFNγ-producing NK cells in the enhancement of the B-cell responses through the potentiation of the B-cell helper properties of neutrophils. These findings suggest that preserved NK cell functions and counts might be required for achieving mAb-induced protective immunity. They open new prospects for improving antiviral immunotherapies. MDPI 2021-02-08 /pmc/articles/PMC7914599/ /pubmed/33567792 http://dx.doi.org/10.3390/vaccines9020137 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Naranjo-Gomez, Mar
Cahen, Marine
Lambour, Jennifer
Boyer-Clavel, Myriam
Pelegrin, Mireia
Immunomodulatory Role of NK Cells during Antiviral Antibody Therapy
title Immunomodulatory Role of NK Cells during Antiviral Antibody Therapy
title_full Immunomodulatory Role of NK Cells during Antiviral Antibody Therapy
title_fullStr Immunomodulatory Role of NK Cells during Antiviral Antibody Therapy
title_full_unstemmed Immunomodulatory Role of NK Cells during Antiviral Antibody Therapy
title_short Immunomodulatory Role of NK Cells during Antiviral Antibody Therapy
title_sort immunomodulatory role of nk cells during antiviral antibody therapy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7914599/
https://www.ncbi.nlm.nih.gov/pubmed/33567792
http://dx.doi.org/10.3390/vaccines9020137
work_keys_str_mv AT naranjogomezmar immunomodulatoryroleofnkcellsduringantiviralantibodytherapy
AT cahenmarine immunomodulatoryroleofnkcellsduringantiviralantibodytherapy
AT lambourjennifer immunomodulatoryroleofnkcellsduringantiviralantibodytherapy
AT boyerclavelmyriam immunomodulatoryroleofnkcellsduringantiviralantibodytherapy
AT pelegrinmireia immunomodulatoryroleofnkcellsduringantiviralantibodytherapy